Treatment of Primary Brain Tumors with Antagonists of Bradykinin-2 Receptors
UAB Research Foundation
posted on 02/22/2012
More than 600,000 people in the U.S. have been diagnosed with primary brain tumors, and approximately 65,000 new cases are identified each year. Brain tumors, while treatable, typically mimic the symptoms of other diseases so that diagnosis is difficult and very often, too late. Researchers at The University of Alabama at Birmingham (UAB) have shown that blocking or genetically altering the receptors for bradykinin inhibits tumor cell growth and spread suggesting antagonists of these receptors can be beneficial for treatment of malignant brain cancers.
- Antagonists of bradykinin-2 receptors inhibit migration and invasion of tumor cells, thus limiting their ability to find blood vessels that provide nutrients required for survival and propagation of satellite tumors.
- Expression of bradykinin-2 receptors correlates with the grade of tumor making it an attractive therapeutic target.
- Treatment can improve prognosis of glial tumors which are the most common and least curable brain cancer.
- This approach may also be effective against other cancers.
- This unique approach can be administered in combination with conventional treatments.
File Number: U2011-0048
Find more innovations